Phase I study of the safety and immunogenicity of AMA-1-C1/hydrogel + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria

Trial Profile

Phase I study of the safety and immunogenicity of AMA-1-C1/hydrogel + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Agatolimod (Primary) ; Aluminium hydroxide (Primary) ; Malaria vaccine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
    • 01 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top